Transmembrane TNF-α: Structure, function and interaction with anti-TNF agents

Takahiko Horiuchi, Hiroki Mitoma, Shin Ichi Harashima, Hiroshi Tsukamoto, Terufumi Shimoda

Research output: Contribution to journalReview article

307 Citations (Scopus)

Abstract

Transmembrane TNF-α, a precursor of the soluble form of TNF-α, is expressed on activated macrophages and lymphocytes as well as other cell types. After processing by TNF-α-converting enzyme (TACE), the soluble form of TNF-α is cleaved from transmembrane TNF-α and mediates its biological activities through binding to Types 1 and 2 TNF receptors (TNF-R1 and -R2) of remote tissues. Accumulating evidence suggests that not only soluble TNF-α, but also transmembrane TNF-α is involved in the inflammatory response. Transmembrane TNF-α acts as a bipolar molecule that transmits signals both as a ligand and as a receptor in a cell-to-cell contact fashion. Transmembrane TNF-α on TNF-α-producing cells binds to TNF-R1 and -R2, and transmits signals to the target cells as a ligand, whereas transmembrane TNF-α also acts as a receptor that transmits outside-to-inside (reverse) signals back to the cells after binding to its native receptors. Anti-TNF agents infliximab, adalimumab and etanercept bind to and neutralize soluble TNF-α, but exert different effects on transmembrane TNF-α-expressing cells (TNF-α-producing cells). In the clinical settings, these three anti-TNF agents are equally effective for RA, but etanercept is not effective for granulomatous diseases. Moreover, infliximab induces granulomatous infections more frequently than etanercept. Considering the important role of transmembrane TNF-α in granulomatous inflammation, reviewing the biology of transmembrane TNF-α and its interaction with anti-TNF agents will contribute to understanding the bases of differential clinical efficacy of these promising treatment modalities.

Original languageEnglish
Article numberkeq031
Pages (from-to)1215-1228
Number of pages14
JournalRheumatology
Volume49
Issue number7
DOIs
Publication statusPublished - Mar 1 2010

Fingerprint

Receptors, Tumor Necrosis Factor, Type II
Ligands
Tumor Necrosis Factor Receptors
Macrophages
Lymphocytes
Inflammation
Infection
Etanercept
Infliximab
tumor necrosis factor precursor
ADAM17 Protein
Adalimumab

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Pharmacology (medical)

Cite this

Transmembrane TNF-α : Structure, function and interaction with anti-TNF agents. / Horiuchi, Takahiko; Mitoma, Hiroki; Harashima, Shin Ichi; Tsukamoto, Hiroshi; Shimoda, Terufumi.

In: Rheumatology, Vol. 49, No. 7, keq031, 01.03.2010, p. 1215-1228.

Research output: Contribution to journalReview article

Horiuchi, Takahiko ; Mitoma, Hiroki ; Harashima, Shin Ichi ; Tsukamoto, Hiroshi ; Shimoda, Terufumi. / Transmembrane TNF-α : Structure, function and interaction with anti-TNF agents. In: Rheumatology. 2010 ; Vol. 49, No. 7. pp. 1215-1228.
@article{5b21dd2cf2234ae282650cd699060abb,
title = "Transmembrane TNF-α: Structure, function and interaction with anti-TNF agents",
abstract = "Transmembrane TNF-α, a precursor of the soluble form of TNF-α, is expressed on activated macrophages and lymphocytes as well as other cell types. After processing by TNF-α-converting enzyme (TACE), the soluble form of TNF-α is cleaved from transmembrane TNF-α and mediates its biological activities through binding to Types 1 and 2 TNF receptors (TNF-R1 and -R2) of remote tissues. Accumulating evidence suggests that not only soluble TNF-α, but also transmembrane TNF-α is involved in the inflammatory response. Transmembrane TNF-α acts as a bipolar molecule that transmits signals both as a ligand and as a receptor in a cell-to-cell contact fashion. Transmembrane TNF-α on TNF-α-producing cells binds to TNF-R1 and -R2, and transmits signals to the target cells as a ligand, whereas transmembrane TNF-α also acts as a receptor that transmits outside-to-inside (reverse) signals back to the cells after binding to its native receptors. Anti-TNF agents infliximab, adalimumab and etanercept bind to and neutralize soluble TNF-α, but exert different effects on transmembrane TNF-α-expressing cells (TNF-α-producing cells). In the clinical settings, these three anti-TNF agents are equally effective for RA, but etanercept is not effective for granulomatous diseases. Moreover, infliximab induces granulomatous infections more frequently than etanercept. Considering the important role of transmembrane TNF-α in granulomatous inflammation, reviewing the biology of transmembrane TNF-α and its interaction with anti-TNF agents will contribute to understanding the bases of differential clinical efficacy of these promising treatment modalities.",
author = "Takahiko Horiuchi and Hiroki Mitoma and Harashima, {Shin Ichi} and Hiroshi Tsukamoto and Terufumi Shimoda",
year = "2010",
month = "3",
day = "1",
doi = "10.1093/rheumatology/keq031",
language = "English",
volume = "49",
pages = "1215--1228",
journal = "Rheumatology",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Transmembrane TNF-α

T2 - Structure, function and interaction with anti-TNF agents

AU - Horiuchi, Takahiko

AU - Mitoma, Hiroki

AU - Harashima, Shin Ichi

AU - Tsukamoto, Hiroshi

AU - Shimoda, Terufumi

PY - 2010/3/1

Y1 - 2010/3/1

N2 - Transmembrane TNF-α, a precursor of the soluble form of TNF-α, is expressed on activated macrophages and lymphocytes as well as other cell types. After processing by TNF-α-converting enzyme (TACE), the soluble form of TNF-α is cleaved from transmembrane TNF-α and mediates its biological activities through binding to Types 1 and 2 TNF receptors (TNF-R1 and -R2) of remote tissues. Accumulating evidence suggests that not only soluble TNF-α, but also transmembrane TNF-α is involved in the inflammatory response. Transmembrane TNF-α acts as a bipolar molecule that transmits signals both as a ligand and as a receptor in a cell-to-cell contact fashion. Transmembrane TNF-α on TNF-α-producing cells binds to TNF-R1 and -R2, and transmits signals to the target cells as a ligand, whereas transmembrane TNF-α also acts as a receptor that transmits outside-to-inside (reverse) signals back to the cells after binding to its native receptors. Anti-TNF agents infliximab, adalimumab and etanercept bind to and neutralize soluble TNF-α, but exert different effects on transmembrane TNF-α-expressing cells (TNF-α-producing cells). In the clinical settings, these three anti-TNF agents are equally effective for RA, but etanercept is not effective for granulomatous diseases. Moreover, infliximab induces granulomatous infections more frequently than etanercept. Considering the important role of transmembrane TNF-α in granulomatous inflammation, reviewing the biology of transmembrane TNF-α and its interaction with anti-TNF agents will contribute to understanding the bases of differential clinical efficacy of these promising treatment modalities.

AB - Transmembrane TNF-α, a precursor of the soluble form of TNF-α, is expressed on activated macrophages and lymphocytes as well as other cell types. After processing by TNF-α-converting enzyme (TACE), the soluble form of TNF-α is cleaved from transmembrane TNF-α and mediates its biological activities through binding to Types 1 and 2 TNF receptors (TNF-R1 and -R2) of remote tissues. Accumulating evidence suggests that not only soluble TNF-α, but also transmembrane TNF-α is involved in the inflammatory response. Transmembrane TNF-α acts as a bipolar molecule that transmits signals both as a ligand and as a receptor in a cell-to-cell contact fashion. Transmembrane TNF-α on TNF-α-producing cells binds to TNF-R1 and -R2, and transmits signals to the target cells as a ligand, whereas transmembrane TNF-α also acts as a receptor that transmits outside-to-inside (reverse) signals back to the cells after binding to its native receptors. Anti-TNF agents infliximab, adalimumab and etanercept bind to and neutralize soluble TNF-α, but exert different effects on transmembrane TNF-α-expressing cells (TNF-α-producing cells). In the clinical settings, these three anti-TNF agents are equally effective for RA, but etanercept is not effective for granulomatous diseases. Moreover, infliximab induces granulomatous infections more frequently than etanercept. Considering the important role of transmembrane TNF-α in granulomatous inflammation, reviewing the biology of transmembrane TNF-α and its interaction with anti-TNF agents will contribute to understanding the bases of differential clinical efficacy of these promising treatment modalities.

UR - http://www.scopus.com/inward/record.url?scp=77954232611&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954232611&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keq031

DO - 10.1093/rheumatology/keq031

M3 - Review article

C2 - 20194223

AN - SCOPUS:77954232611

VL - 49

SP - 1215

EP - 1228

JO - Rheumatology

JF - Rheumatology

SN - 1462-0324

IS - 7

M1 - keq031

ER -